The US Food and Drug Administration has listed Indian drugmaker Sun Pharmaceutical Industries' Halol facility in Gujarat under an import alert. It means future shipments of products made at the facility can be refused admission to the US market until the facility becomes compliant with Current Good Manufacturing Practice regulations. The FDA has excluded 14 products from the import alert.